Jubilant Radiopharma

Jubilant Radiopharma is a division of Jubilant Pharma Limited, a global pharmaceutical company headquartered in Singapore. It is an industry-leading radiopharmaceutical business comprising development, manufacturing, and commercialization of radiopharmaceutical products through its Radiopharmaceuticals business. Jubilant Radiopharma's manufactured products are utilized in the diagnosis, treatment, and monitoring of various diseases, specializing in lung, thyroid, bone, and cardiac imaging products, as well as thyroid disease therapy.

Jubilant Radiopharma's Radiopharmaceuticals business includes innovative imaging agents such as Neuraceq, an FDA-approved agent for detecting beta-amyloid plaques in the brain for evaluating Alzheimer's disease. As of July 2024, Neuraceq became available at Jubilant's manufacturing site in Mobile, AL, expanding its supply capabilities to meet increasing demand.

Furthermore, Jubilant Radiopharma's Radiopharmacies business is the second-largest radiopharmacy network in the US, owning and operating 46 radiopharmacies across 21 states. This division distributes nuclear medicine products to major group purchasing organizations, health systems, imaging centers, cardiologists, and hospitals, serving over four million patients yearly.

In June 2023, Jubilant Radiopharma announced a collaboration with Evergreen Theragnostics to prepare, sell, and distribute doses of OCTEVY (Kit for Preparation of Ga 68 DOTATOC Injection), pending FDA approval in the second half of 2023, for localization of neuroendocrine tumors.

Additionally, Jubilant Radiopharma received FDA clearance in June 2023 to use its RUBY Rubidium Elution System and RUBY-FILL (Rubidium Rb82 generator) in mobile settings, enabling cardiac PET imaging in smaller community hospitals and rural areas.